Replies to post #4991 on Dendreon Corp fka DNDNQ

[walldiver]

TTP isn't the primary endpoint, and it seems that the company doesn't want to jeopardize the integrity of the survival data in the FDA's eyes by unblinding 9902B early to look at TTP. DNDN keeps talking about the survival data in 2H 2008, so I'd take them at their word.